Remicaide (infliximab) ( DrugBank: Infliximab )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 39 | Toxic epidermal necrolysis | 1 |
39. Toxic epidermal necrolysis
Clinical trials : 13 / Drugs : 19 - (DrugBank : 8) / Drug target genes : 11 - Drug target pathways : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00372723 (ClinicalTrials.gov) | July 2006 | 5/9/2006 | Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) | Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis | Toxic Epidermal Necrolysis | Drug: Remicaide (infliximab) | Loyola University | NULL | Withdrawn | 18 Years | N/A | Both | 0 | Phase 2 | United States |